.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The BEST-CLI randomized trial compared surgical and endovascular revascularization strategies in patients with chronic limb-threatening ischaemia. The study was designed to provide modern comparative evidence in a field where both approaches are widely used and where patient anatomy and conduit availability strongly influence treatment choice. In patients with a suitable single-segment saphenous vein, surgical bypass provided better limb-related outcomes than an endovascular-first strategy. In the broader population, outcomes were more balanced when an adequate surgical conduit was not available. For surgeons, the important lesson is that there is no universal winner between open and endovascular revascularization. The patient's vascular anatomy, conduit quality, procedural risk, life expectancy, comorbidities and local expertise all matter. The trial supports a shared, anatomy-driven decision rather than a blanket “endovascular first” or “surgery first” rule. It also highlights the value of multidisciplinary vascular teams capable of offering both approaches. BEST-CLI is especially relevant to ASICON's vascular and endovascular training because it demonstrates how randomized evidence can help determine which technology or operation is most appropriate for a specific patient.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The BEST-CLI randomized trial compared surgical and endovascular revascularization strategies in patients with chronic limb-threatening ischaemia. The study was designed to provide modern comparative evidence in a field where both approaches are widely used and where patient anatomy and conduit availability strongly influence treatment choice. In patients with a suitable single-segment saphenous vein, surgical bypass provided better limb-related outcomes than an endovascular-first strategy. In the broader population, outcomes were more balanced when an adequate surgical conduit was not available. For surgeons, the important lesson is that there is no universal winner between open and endovascular revascularization. The patient's vascular anatomy, conduit quality, procedural risk, life expectancy, comorbidities and local expertise all matter. The trial supports a shared, anatomy-driven decision rather than a blanket “endovascular first” or “surgery first” rule. It also highlights the value of multidisciplinary vascular teams capable of offering both approaches. BEST-CLI is especially relevant to ASICON's vascular and endovascular training because it demonstrates how randomized evidence can help determine which technology or operation is most appropriate for a specific patient.
Yesterday
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
